In scientific articles and blog posts on the subject of hemp is also increasingly CBDa the speech. This is an original form of the CBD.
We summarize below what is currently known about this ingredient and why it may be of interest to you in the future.
The extraction of ingredients from the hemp leaves
For the extraction of cannabidiols, the low THC useful hemp is used. In the leaves of the plant cannabidiol is present in its original form. This is known as CBDa.
From a biochemical point of view, it is a so-called carboxylic acid. Carboxylic acids are organic compounds widely found in nature. You may know the names formic acid and acetic acid. They also belong to the carboxylic acid family.
All carboxylic acids have a different number of carbon molecules and are structured in a specific chemical form. They all have a so-called carboxy group.
You can imagine this carboxy group in the structure of carboxylic acids as a characteristic component that characterizes all acids of this type. It is indicated in a chemical formula with the letters -COOH.
In connection with CBDa, the term "acidic precursor" to CBD is often used. Substances are acidic if they have a PH value below 7. The indication of a precursor indicates that a final form of cannabidiol must first be isolated from its original form in a chemical process.
Various extraction methods are available here. Common to all methods is that a process known as decarboxylation occurs. In this process, for example, the above-mentioned carboxy group is separated from the carboxylic acid by heating.
Only then is cannabidiol activated.
Does the precursor have its own spectrum of activity?For a long time, the original cannabidiol has received little attention from experts and scientists. It was simply considered to be the original active substance in the green cannabis leaves, which had not previously been attributed any functions of its own.
How little significance this preliminary stage was considered, can also be seen from the designation "inactive"... The original form was considered inactive and less interesting form of a cannabidiol.
This assessment is gradually changing. To understand this, it is useful to take a closer look at the potential effects of cannabinoids in the human organism.
Where do the ingredients of useful hemp plants start in the human body?
When biochemical substances produce effects in our organism, this usually happens in a very specific way. The substances can only pass on their information if they find suitable sites in the body to which they can bind.
In this context we speak of receptors.
Just like a key fits into a lock, these receptors have a surface that exactly matches the surface of certain active ingredients. Similar to a ship in a port, the biochemical substances dock there and can produce an effect.
Maybe you know from cannabinoids that they match the so-called CB1 receptors in the human brain and CB2 receptors in other parts of our organism. In this context, the TRPA1 and TRPM8 receptors, which are open to the active substances from the commercial hemp plant, are also mentioned. The latter docking points have to do with, among other things, our perception of pain.
There is also evidence that cannabinoids may also inhibit certain enzymes. Enzymes have the task of mediating and promoting certain reactions in the human body.
The development of pain and the manifestation of inflammation are very simply connected in the human body with the release of certain signal substances.
The enzymes Cox-1 and Cox-2 are particularly important in inflammatory reactions. Among other things, these also occupy receptor sites and thus pass on their information.
If, for example, plant substances such as cannabinoids succeed in displacing other signalling substances from the receptors or inhibiting them altogether, then pain and inflammation cascades can be interrupted.
The receptor sites are blocked, and in some cases the formation of the signalling substances is also inhibited.
According to recent findings, CBD and its original form are probably both able to dock to many receptors. This should apply in particular to the TRPA1 and TRPM8 receptors. Especially the cannabidiol precursor can, according to the latest findings, also act on Cox-1 and Cox-2.
Study: The precursor milder aggressive breast cancer cells
A Japanese study from 2017 shows that CBDa inhibits the aggressiveness of a breast cancer line by acting on the Cox-1 and Cox-2 enzymes, among others. These enzymes are not only involved in the development of inflammation, but also complicated metabolic processes in cancer cells.
The study was able to show that CBDa can reduce the aggressive character of breast cancer.
This effect seems possible because the Cox enzymes are supposed to stimulate the formation of new blood vessels in the cancer cells. The cannabinoid in its original form can hinder the formation of these blood vessels by inhibiting the Cox enzymes.
But here is Further research needed. From the beginning, however, especially the effect on the Cox enzymes can make very interesting application possibilities of the inactive agent in hemp possible.
Classic Painkillers are also known as Cox inhibitors. Here are a number of anti-inflammatory drugs without cortisone, such as Diclofenac. These drugs often have unpleasant side effects in the stomach area.
If a supportive function in the field of cannabidiols could be found here, the use of classical Cox inhibitors could possibly be reduced in the future.
However, this thesis still needs further scientific support because too few studies have been carried out. Since both cannabinoids are active at the same receptor sites, we hope to gain new insights into Effect of the precursor.
This would also be interesting under the aspect that the processing steps in the extraction of cannabidiols could possibly be reduced.
At present the available oils as a rule, value on a high Purity level of CBD laid.
A number of studies are already known about this and the effects are very well documented in some areas. The cannabinoid in its original form present in hemp is usually only present in traces in these products and is not separately identified.
If the indications of positive effects are substantiated here, we can look forward to other products that also show the content of the precursor separately.
Even the precursor of the active ingredient is not contaminated with THC and can open up a further interesting field of application for products made from commercial hemp.
Conclusion: An active ingredient with its own potentialThe preliminary stage of the most common cannabidiols CBD with the small addition "a" seems to have its own spectrum of activity according to the latest findings. In the future, interesting applications can be expected after the completion of further studies.
If you have already made positive experiences with hemp products, we recommend that you also use the Development of CBDa to keep an eye on him. Under certain circumstances, combinations of both substances will lead to products that can support your own health even better.
Mono products with the preliminary stage may be conceivable here, but that cannot be said with certainty at present. We will also continue to pursue this topic.
Note: In this article we report on prescription cannabis, prescription CBD or over-the-counter or legal CBD. This Article does not make any proposal as to the possible purpose of the proposal and is for information and education purposes only. Promises of healing and benefits are excluded.